EP Patent

EP2646031A4 — INCREASING THE PHARMACOLOGICAL BIODAPABILITY OF A NALTREXONE TREATMENT

Assigned to Orexigen Therapeutics Inc · Expires 2014-04-23 · 12y expired

What this patent protects

Patent listed against chembl-chembl2103744.

Drugs covered by this patent

chembl-chembl2103744 (MORPHINE SULFATE)

Patent Metadata

Patent number: EP2646031A4
Jurisdiction: EP
Classification: —
Expires: 2014-04-23
Drug substance claim: No
Drug product claim: No
Assignee: Orexigen Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.